Stocks · News reference
Cramer calls Nuvation Bio a pure spec, prefers CoreWeave over IREN, is unsure on Seneca, cautious on NuScale, and approves Box.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Box stock rose 1.18% on Wednesday following second-quarter earnings that met expectations. The company reported record revenue of $321 million (up 9% YoY) and adjusted net income of $0.40 per share. Box raised full-year revenue guidance to $1.29 billion but slightly lowered profitability guidance to $1.54 per share. Growth was driven by adoption of the Enterprise Advanced plan as clients scale AI capabilities.
Morgan Stanley analyst Josh Baer maintains Box (NYSE:BOX) with a Equal-Weight and raises the price target from $33 to $36.
Citigroup analyst Steven Enders maintains Box (NYSE:BOX) with a Buy and raises the price target from $37 to $40.
The ongoing Nvidia stock surge has pushed Jensen Huang's net worth by over $48 billion and is the eighth-richest man in the world.
OpenAI's Sam Altman warns the AI infrastructure boom may be unsustainable, putting speculative neoclouds plays at risk.
Nebius and CoreWeave are neocloud infrastructure companies benefiting from surging AI data center demand, with the market expected to grow at a 58% CAGR through 2031. Nebius has outperformed with 146% gains in 2026 and improving profitability, while CoreWeave trades cheaper but faces higher losses despite a stronger revenue backlog of $104 billion. Both stocks offer long-term growth potential depending on investor risk profile.